Drug General Information |
Drug ID |
D02HVH
|
Former ID |
DNC006969
|
Drug Name |
7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C16H20N2OS2
|
Canonical SMILES |
C1=CC=C(C=C1)C2=CSC(=N2)NC(=O)CCCCCCS
|
InChI |
1S/C16H20N2OS2/c19-15(10-6-1-2-7-11-20)18-16-17-14(12-21-16)13-8-4-3-5-9-13/h3-5,8-9,12,20H,1-2,6-7,10-11H2,(H,17,18,19)
|
InChIKey |
LUXAHBUKMVESIS-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Histone deacetylase 4 |
Target Info |
Inhibitor |
[1]
|
Histone deacetylase 6 |
Target Info |
Inhibitor |
[1]
|
Histone deacetylase 1 |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Alcoholism
|
Epstein-Barr virus infection
|
Viral carcinogenesis
|
MicroRNAs in cancerhsa05034:Alcoholism
|
Viral carcinogenesishsa04110:Cell cycle
|
Notch signaling pathway
|
Thyroid hormone signaling pathway
|
Huntington's disease
|
Amphetamine addiction
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
MicroRNAs in cancer
|
Chronic myeloid leukemia
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_11:TCR Signaling Pathway
|
PANTHER Pathway
|
Wnt signaling pathway
|
p53 pathway
|
Pathway Interaction Database
|
Signaling events mediated by HDAC Class II
|
Signaling events mediated by HDAC Class III
|
Signaling events mediated by HDAC Class I
|
Sumoylation by RanBP2 regulates transcriptional repression
|
Validated nuclear estrogen receptor alpha networkhdac_classii_pathway:Signaling events mediated by HDAC Class II
|
Signaling events mediated by HDAC Class Ismad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
Notch signaling pathway
|
E2F transcription factor network
|
Presenilin action in Notch and Wnt signaling
|
Regulation of Telomerase
|
Glucocorticoid receptor regulatory network
|
Regulation of Androgen receptor activity
|
IL3-mediated signaling events
|
Validated nuclear estrogen receptor alpha network
|
Retinoic acid receptors-mediated signaling
|
Hedgehog signaling events mediated by Gli proteins
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
Validated targets of C-MYC transcriptional repression
|
Regulation of retinoblastoma protein
|
Notch-mediated HES/HEY network
|
Reactome
|
NOTCH1 Intracellular Domain Regulates Transcription
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
Constitutive Signaling by NOTCH1 HD+PEST Domain MutantsR-HSA-2122947:NOTCH1 Intracellular Domain Regulates Transcription
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
Assembly of the primary ciliumR-HSA-1538133:G0 and Early G1
|
p75NTR negatively regulates cell cycle via SC1
|
Formation of the beta-catenin:TCF transactivating complex
|
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
|
HDACs deacetylate histones
|
Deactivation of the beta-catenin transactivating complex
|
NoRC negatively regulates rRNA expression
|
RNA Polymerase I Transcription Initiation
|
Factors involved in megakaryocyte development and platelet production
|
WikiPathways
|
Endochondral Ossification
|
Cardiac Hypertrophic Response
|
Neural Crest Differentiation
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in lymphocytes - TarBase
|
miR-targeted genes in epithelium - TarBase
|
TarBasePathway
|
Cell Cycle
|
MicroRNAs in cardiomyocyte hypertrophyWP2858:Ectoderm Differentiation
|
Cell CycleWP706:SIDS Susceptibility Pathways
|
Notch Signaling Pathway
|
TGF beta Signaling Pathway
|
IL-6 signaling pathway
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
|
Notch Signaling Pathway
|
Retinoblastoma (RB) in Cancer
|
TWEAK Signaling Pathway
|
Integrated Breast Cancer Pathway
|
Signalling by NGF
|
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
|
Mitotic G1-G1/S phases
|
Factors involved in megakaryocyte development and platelet production
|
Androgen receptor signaling pathway
|
References |
REF 1 | J Med Chem. 2007 Nov 1;50(22):5425-38. Epub 2007 Oct 11.Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. |